A Phase 3 interventional study of Ocrelizumab and Ocrelizumab Placebo in Relapsing-remitting Multiple Sclerosis, sponsored by Hoffmann-La Roche. Active, not recruiting at 71 sites in 25 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 7th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:
Celltrion · Sites in Poland
Ages 18–55
University of California, San Francisco · Sites in United States
Ages 18–65
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2022.
This study's enrollment of 188 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 404 across the 10 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche: 2 open now, 5 under way, 2 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 3, and was the 10th registered.
Hoffmann-La Roche’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2004.
3 of the studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05906992Phase 3CelltrionA Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | 2027-02 |
| NCT05296161Amsterdam UMC, location VUmcB Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis | 2027-02 |
| NCT06495593University of California, San FranciscoEffects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 14 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and \< 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks.
This Phase III randomized, double-blind, double-dummy, multicenter study will evaluate the safety and efficacy of ocrelizumab administered as intravenous (IV) infusion every 24 weeks (Q24W) compared with fingolimod taken orally (PO), once daily (QD), in children and adolescents with RRMS aged between 10 and \< 18 years. Participants will be randomized in a 1:1 ratio (ocrelizumab:fingolimod), globally. This study consists of a double-blind, double dummy period in which participants will be treated with either active ocrelizumab or active fingolimod for a flexible duration. Participants who complete the double-blind period will be offered the possibility to enter an optional open-label extension (OLE) treatment period of at least 144 weeks with ocrelizumab.
Inclusion Criteria:
Inclusion Criteria for Optional OLE Period:
-Participants in Group A (ocrelizumab in the DBP) and Group B (fingolimod in the DBP) who, in the opinion of the investigator, may benefit from switching to ocrelizumab and who have completed the DBP with study treatment (ocrelizumab/fingolimod), may participate in the OLE period
Exclusion Criteria:
Exclusion Criteria for Optional OLE Period:
-Participants who have discontinued the study during the DBP
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ocrelizumab, as IV infusion Q24W. The first dose is given as dual infusions of half the dose of ocrelizumab on Days 1 and 15, and subsequent doses are given as single infusions of ocrelizumab Q24W. Participants will also receive a placebo of fingolimod administered as QD capsule.
Drug: Ocrelizumab · Other: Fingolimod Placebo
Participants will receive fingolimod PO, QD as per the prescribing information provided with fingolimod. Participants will also receive a placebo of ocrelizumab administered as IV infusion on Days 1 and 15, and Q24W thereafter.
Other: Ocrelizumab Placebo · Drug: Fingolimod
Ocrelizumab, 300 milligrams (mg) will be administered as IV infusion to participants who weigh \< 35 kilograms (kg), and ocrelizumab 600 mg, IV will be administered to participants who weigh ≥ 35 kg on Days 1 and 15 (half the dose, 2 weeks apart), and Q24W thereafter.
Also known as: RO4964913; Ocrevus
Ocrelizumab matching placebo will be administered as IV infusion on Day 1 and Day 15, and Q24W thereafter.
Fingolimod will be administered QD as a capsule per the prescribing information (0.25 mg to participants who weigh ≤ 40 kg and 0.5 mg to participants who weigh \> 40 kg).
Also known as: Gilenya®
Fingolimod matching placebo will be administered QD as a capsule.
Protocol-defined Annualized Relapse Rate (ARR)
The population-level summary is rate ratio of ARR. The ARR is calculated as the total number of protocol-defined relapses divided by the total patient-years. Protocol-defined relapse is the occurrence of new/worsening neurological symptoms attributable to multiple sclerosis (MS) and immediately preceded by relatively stable or improving neurological state for ≥ 30 days. Symptoms must persist for \>24 hours \& should not be attributable to confounding clinical factors. The new/worsening neurological symptoms must be accompanied by objective neurological worsening consistent with an increase of at least half a step on the expanded disability status scale (EDSS) score, or 2 points on one of the appropriate functional system (FS) scores, or 1 point on two or more of the appropriate FS scores. The change must affect the selected FS (i.e., pyramidal, ambulation, cerebellar, brainstem, sensory, or visual). Adjusted values were reported. OM assessed non inferiority of ocrelizumab vs fingolimod.
Time frame: Up to after the last participant randomized completed 24 weeks since first study treatment administration (up to approximately 160 weeks)
Protocol-defined ARR
The population-level summary is rate ratio of ARR. The ARR is calculated as the total number of protocol-defined relapses divided by the total patient-years. Protocol-defined relapse is the occurrence of new/worsening neurological symptoms attributable to multiple sclerosis (MS) and immediately preceded by relatively stable or improving neurological state for ≥ 30 days. Symptoms must persist for \>24 hours \& should not be attributable to confounding clinical factors. The new/worsening neurological symptoms must be accompanied by objective neurological worsening consistent with an increase of at least half a step on the expanded disability status scale (EDSS) score, or 2 points on one of the appropriate functional system (FS) scores, or 1 point on two or more of the appropriate FS scores. The change must affect the selected FS (i.e., pyramidal, ambulation, cerebellar, brainstem, sensory, or visual). Adjusted values were reported. OM assessed non superiority of ocrelizumab vs fingolimod.
Time frame: Up to after the last participant randomized completed 24 weeks since first study treatment administration (up to approximately 160 weeks)
Number of New or Enlarging T2-hyperintense Lesions (T2 Lesions), as Detected by Brain Magnetic Resonance Imaging (MRI)
Number of new or enlarging T2 lesions for each participant was calculated as the sum of the individual number of new or enlarging T2 lesions as detected by brain MRI.
Time frame: Up to after the last participant randomized completed 24 weeks since first study treatment administration (up to approximately 160 weeks)
Number of T1 Gd Lesions at Week 12
Brain MRI with and without a Gd-contrast agent were performed to assess the number of Gd lesions.
Time frame: At Week 12
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to approximately 7 years
Maximum Serum Concentration (Cmax) of Ocrelizumab
Time frame: Cycle (1 Cycle=24 weeks)
Area Under the Plasma Concentration-time Curve Over a Dosing Interval (AUC Tau) of Ocrelizumab
Time frame: Cycle 1 (1 Cycle=24 weeks)
Number of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab
Participants were considered to be ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA response). The total number of participants who developed ADAs to atezolizumab was determined by summing the ADA-positive participants across all timepoints.
Time frame: Up to approximately 7 years
Levels of Cluster of Differentiation 19 (CD19) + B-cell Count in Blood
CD19+ B-cell count in blood will be assessed using flow cytometry.
Time frame: Up to approximately 7 years
A total of 187 participants with relapsing-remitting multiple sclerosis (RRMS) took part in the study at 79 investigative sites across 25 countries.
| Milestone | Ocrelizumab | Fingolimod |
|---|---|---|
| Started | 93 | 94 |
| Safety-evaluable (se) population | 93 | 92 |
| Completed | 0 | 0 |
| Not completed | 93 | 94 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Reason not specified | 1 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 8 |
| Withdrew: Ongoing in study | 89 | 81 |
The population-level summary is rate ratio of ARR. The ARR is calculated as the total number of protocol-defined relapses divided by the total patient-years. Protocol-defined relapse is the occurrence of new/worsening neurological symptoms attributable to multiple sclerosis (MS) and immediately preceded by relatively stable or improving neurological state for ≥ 30 days. Symptoms must persist for \>24 hours \& should not be attributable to confounding clinical factors. The new/worsening neurological symptoms must be accompanied by objective neurological worsening consistent with an increase of at least half a step on the expanded disability status scale (EDSS) score, or 2 points on one of the appropriate functional system (FS) scores, or 1 point on two or more of the appropriate FS scores. The change must affect the selected FS (i.e., pyramidal, ambulation, cerebellar, brainstem, sensory, or visual). Adjusted values were reported. OM assessed non superiority of ocrelizumab vs fingolimod.
| relapses per patient-year | Ocrelizumab | Fingolimod |
|---|---|---|
| Protocol-defined ARR | 0.070 (0.034 to 0.144) | 0.135 (0.075 to 0.243) |
Number of new or enlarging T2 lesions for each participant was calculated as the sum of the individual number of new or enlarging T2 lesions as detected by brain MRI.
| lesions | Ocrelizumab | Fingolimod |
|---|---|---|
| Number of New or Enlarging T2-hyperintense Lesions (T2 Lesions), as Detected by Brain Magnetic Resonance Imaging (MRI) | 495 | 908 |
Brain MRI with and without a Gd-contrast agent were performed to assess the number of Gd lesions.
| lesions | Ocrelizumab | Fingolimod |
|---|---|---|
| Number of T1 Gd Lesions at Week 12 | 5 | 33 |
An AE was defined as any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Results for this outcome have not been posted.
| micrograms per milliliter (µg/ml) | Ocrelizumab |
|---|---|
| Maximum Serum Concentration (Cmax) of Ocrelizumab | 142 ± 0.173 |
| µg/mL.day | Ocrelizumab |
|---|---|
| Area Under the Plasma Concentration-time Curve Over a Dosing Interval (AUC Tau) of Ocrelizumab | 3020 ± 0.266 |
Participants were considered to be ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA response). The total number of participants who developed ADAs to atezolizumab was determined by summing the ADA-positive participants across all timepoints.
Results for this outcome have not been posted.
CD19+ B-cell count in blood will be assessed using flow cytometry.
Results for this outcome have not been posted.
The population-level summary is rate ratio of ARR. The ARR is calculated as the total number of protocol-defined relapses divided by the total patient-years. Protocol-defined relapse is the occurrence of new/worsening neurological symptoms attributable to multiple sclerosis (MS) and immediately preceded by relatively stable or improving neurological state for ≥ 30 days. Symptoms must persist for \>24 hours \& should not be attributable to confounding clinical factors. The new/worsening neurological symptoms must be accompanied by objective neurological worsening consistent with an increase of at least half a step on the expanded disability status scale (EDSS) score, or 2 points on one of the appropriate functional system (FS) scores, or 1 point on two or more of the appropriate FS scores. The change must affect the selected FS (i.e., pyramidal, ambulation, cerebellar, brainstem, sensory, or visual). Adjusted values were reported. OM assessed non inferiority of ocrelizumab vs fingolimod.
| relapses per patient-year | Ocrelizumab | Fingolimod |
|---|---|---|
| Protocol-defined Annualized Relapse Rate (ARR) | 0.070 (0.034 to 0.144) | 0.135 (0.075 to 0.243) |
Collected over Up to approximately 160 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocrelizumab | 0/93 (0%) | 6/93 (6.5%) | 76/93 (81.7%) |
| Fingolimod | 0/92 (0%) | 8/92 (8.7%) | 65/92 (70.7%) |
| Event | Ocrelizumab | Fingolimod |
|---|---|---|
| PneumoniaInfections and infestations | 2/93 | 1/92 |
| NeutropeniaBlood and lymphatic system disorders | 0/93 | 1/92 |
| Sinus bradycardiaCardiac disorders | 0/93 | 1/92 |
| General physical health deteriorationGeneral disorders | 0/93 | 1/92 |
| ConjunctivitisInfections and infestations | 0/93 | 1/92 |
| Dengue feverInfections and infestations | 0/93 | 1/92 |
| InfluenzaInfections and infestations | 0/93 | 1/92 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/93 | 1/92 |
| Electrocardiogram QT prolongedInvestigations | 0/93 | 1/92 |
| Transaminases increasedInvestigations | 0/93 | 1/92 |
| Event | Ocrelizumab | Fingolimod |
|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 45/93 | 22/92 |
| Upper respiratory tract infectionInfections and infestations | 29/93 | 25/92 |
| HeadacheNervous system disorders | 27/93 | 23/92 |
| NasopharyngitisInfections and infestations | 19/93 | 14/92 |
| Multiple sclerosis relapseNervous system disorders | 10/93 | 14/92 |
| InfluenzaInfections and infestations | 13/93 | 5/92 |
| NauseaGastrointestinal disorders | 7/93 | 11/92 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/93 | 9/92 |
| FatigueGeneral disorders | 9/93 | 7/92 |
| SinusitisInfections and infestations | 9/93 | 3/92 |
Full Analysis Set (FAS) included all randomized participants, with participants grouped according to their assigned treatment.
| Age, Continuous(years) | Ocrelizumab | Fingolimod | Total |
|---|---|---|---|
| Mean | 15.0 ± 1.5 | 15.0 ± 1.5 | 15.0 ± 1.5 |
| Sex: Female, Male(Participants) | Ocrelizumab | Fingolimod | Total |
|---|---|---|---|
| Female | 67 | 62 | 129 |
| Male | 26 | 32 | 58 |
| Ethnicity (NIH/OMB)(Participants) | Ocrelizumab | Fingolimod | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 18 | 44 |
| Not Hispanic or Latino | 50 | 55 | 105 |
| Unknown or Not Reported | 17 | 21 | 38 |
| Race (NIH/OMB)(Participants) | Ocrelizumab | Fingolimod | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 3 | 7 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 6 | 9 |
| White | 63 | 60 | 123 |
| More than one race | 6 | 4 | 10 |
| Unknown or Not Reported | 16 | 20 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from May 2022 to primary completion in Jun 2025, 36 months.
Results were first posted in Jul 2026, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 36 months is close to that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Relapsing-Remitting →